DrugPatentWatch Database Preview

ARANESP Drug Profile

« Back to Dashboard

Summary for Tradename: ARANESP

Patents:	94
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ARANESP
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARANESP

Recent Clinical Trials for ARANESP

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Zealand University Hospital	N/A
Alberta Children's Hospital	Phase 2
Leiden University Medical Center	Phase 2/Phase 3

See all ARANESP clinical trials

Recent Litigation for ARANESP

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Ameranth, Inc. v. Starbucks Corporation	2013-05-06

See all ARANESP litigation

Pharmacology for ARANESP

Ingredient-type	Erythropoietin
Physiological Effect	Increased Erythroid Cell Production

Company Disclosures: US Patents for ARANESP

These patents were extracted from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		Kirin-Amgen, Inc. (Thousand Oaks, CA)	2003-12-13	RX		company
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		Amgen Inc. (Thousand Oaks, CA)	2024-05-15	RX		company
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	002	2001-09-17		Kirin-Amgen, Inc. (Thousand Oaks, CA)	2003-12-13	RX		company
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	002	2001-09-17		Amgen Inc. (Thousand Oaks, CA)	2024-05-15	RX		company
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	003	2001-09-17		Kirin-Amgen, Inc. (Thousand Oaks, CA)	2003-12-13	RX		company
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	003	2001-09-17		Amgen Inc. (Thousand Oaks, CA)	2024-05-15	RX		company

Patent Text Search: US Patents for ARANESP

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)	2033-03-11	RX		search
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		AMGEN INC. (Thousand Oaks, CA)	2039-02-26	RX		search
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17			2036-04-01	RX		search
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		YALE UNIVERSITY (New Haven, CT)	2039-02-26	RX		search
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		GENOSCIENCE PHARMA (Marseilles, FR)	2039-02-26	RX		search
Amgen	ARANESP	darbepoetin alfa	VIAL; INTRAVENOUS	103951	001	2001-09-17		ChemoCentryx, Inc. (Mountain View, CA)	2036-06-13	RX		search

International Patents for ARANESP

Country	Patent Number	Estimated Expiration
Hungary	204889
Slovenia	3494986
European Patent Office	1907009
Japan	H0693000
Australia	2007336873
Austria	498620

Supplementary Protection Certificates for ARANESP

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2004015	Lithuania		PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
43/2001	Austria		PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
132001900976055	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/185/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19- 20-21-22-23-24-25-26-27-28-29-30, 20010608
SPC028/2001	Ireland		SPC028/2001: 20031204, EXPIRES: 20160607
SZ 43/2001	Austria		PRODUCT NAME: DARBEPOETIN-ALFA
10199059	Germany		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608